In September 2023, investment management firm Foundry Partners LLC disclosed its acquisition of a new stake in shares of InMode Ltd. (NASDAQ: INMD) during the second quarter. According to the company’s recent 13F filing with the Securities and Exchange Commission (SEC), Foundry Partners purchased 90,720 shares of InMode’s healthcare stock, amounting to approximately $3,388,000 in value. This purchase accounted for roughly 0.11% ownership of InMode at the end of the quarter.
InMode, a leading medical technology company, recently released its quarterly earnings data on July 27th. The healthcare firm reported earnings per share (EPS) of $0.65 for the quarter, meeting analysts’ consensus estimates. Additionally, InMode generated revenue of $136.08 million during this period, slightly surpassing analyst projections of $135.80 million. Notably, InMode boasted an impressive net margin of 36.77% and a return on equity of 35.03%. Analysts predict that InMode Ltd.’s fiscal year will result in an EPS of 2.45.
Based in the United States but operating internationally as well, InMode specializes in designing, developing, manufacturing, and marketing minimally invasive aesthetic medical products utilizing their proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company’s product line encompasses various procedures such as liposuction with simultaneous skin tightening, body and face contouring treatments, ablative skin rejuvenation treatments, and applications within women’s health conditions and procedures.
By leveraging their innovative technologies and extensive product range, InMode seeks to address the rising demand for minimally invasive alternatives within the aesthetic medical field worldwide.
https://beststocks.com/investment-management-firm-foundry-partners-acquir/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.